Cited by 362Birth, Development, and HealthPregnancy and preeclampsia studiesCardiovascular Conditions and Treatments

Long-term cardiovascular consequences of fetal growth restriction: biology, clinical implications, and opportunities for prevention of adult disease

Open access
Crispi, Fatima, Miranda, Jezid, Gratacós, Eduard·2018·American Journal of Obstetrics and Gynecology

Abstract

In the modern world, cardiovascular disease is a leading cause of death for both men and women. Epidemiologic studies consistently have suggested an association between low birthweight and/or fetal growth restriction and increased rate of cardiovascular mortality in adulthood. Furthermore, experimental and clinical studies have demonstrated that sustained nutrient and oxygen restriction that are associated with fetal growth restriction activate adaptive cardiovascular changes that might explain this association. Fetal growth restriction results in metabolic programming that may increase the risk of metabolic syndrome and, consequently, of cardiovascular morbidity in the adult. In addition, fetal growth restriction is strongly associated with fetal cardiac and arterial remodeling and a subclinical state of cardiovascular dysfunction. The cardiovascular effects ocurring in fetal life, includes cardiac morphology changes, subclinical myocardial dysfunction, arterial remodeling, and impaired endothelial function, persist into childhood and adolescence. Importantly, these changes have been described in all clinical presentations of fetal growth restriction, from severe early- to milder late-onset forms. In this review we summarize the current evidence on the cardiovascular effects of fetal growth restriction, from subcellular to organ structure and function as well as from fetal to early postnatal life. Future research needs to elucidate whether and how early life cardiovascular remodeling persists into adulthood and determines the increased cardiovascular mortality rate described in epidemiologic studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajog.2017.12.012

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Fetal growth restriction is associated with metabolic programming that increases the risk of future development of metabolic syndrome and consequent cardiovascular and endocrine diseases.

    “It has been associated with metabolic programming that increases the risk of future development of metabolic syndrome and consequent cardiovascular and endocrine diseases.11,12”

    From Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction (2020) · cites this paper as [12]

    The Abstract states that fetal growth restriction causes metabolic programming that may increase the risk of metabolic syndrome and, consequently, adult cardiovascular morbidity. The Fetal Programming of Adult Cardiovascular Disease section also discusses diabetes as a metabolic disease, but does not say that metabolic syndrome leads to endocrine diseases. The claim therefore adds an unsupported consequence and is more certain than the paper’s qualified statement. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Preterm birth and FGR are clinically observable sentinel phenotypes that may reflect several adverse maternal-placental-fetal pathways and are themselves associated with long-term cardiometabolic risk.

    “Preterm birth and FGR are clinically observable sentinel phenotypes that may reflect several adverse maternal–placental–fetal pathways and are themselves associated with long-term cardiometabolic risk [97,98,99,100,101].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 158 · Cited by 362

Research works printed but not linked: 4

  1. [39]39. Tang X, Hernandez-Andrade E, Ahn H, et al. Intermediate diastolic velocity as a parameter of cardiac dysfunction in growth-restricted fetuses. Fetal Diagn Ther 2016;39:28-39.
  2. [63]63. Expert Reviews ajog.org S874 American Journal of Obstetrics & Gynecology FEBRUARY 2018
  3. [147]147. Gilsbach R, Preissl S, Grüning BA, et al. Dynamic DNA methylation orchestrates car- diomyocyte development, maturation and dis- ease. Nat Commun 2014;5:5288.
  4. [157]157. Skilton MR, Ayer JG, Harmer JA, et al. Impaired fetal growth and arterial wall thickening: a randomized trial of u-3 supplementation. Pe- diatrics 2012;129:e698-70. 110. ajog.org Expert Reviews

Authors
Crispi, F., Miranda, J., & Gratacós, E.
Affiliations
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
Corresponding author
Crispi, Fatima
Venue
American Journal of Obstetrics and Gynecology
Publisher
Elsevier BV
Published
2018-02
Volume
218
Issue
2
Pages
S869-S879
ISSN
0002-9378 (ISSN-L)
OpenAlex
W2790251179
Cited by
362
References
158
Citations by year
2026: 38 · 2025: 51 · 2024: 44 · 2023: 43 · 2022: 47 · 2021: 52 · 2020: 50 · 2019: 25 · 2018: 12
FWCI
6.64
Type
journal article
Language
en
Open access
Locations
  • American Journal of Obstetrics and Gynecology (publishedVersion)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc-nd)
Funders
  • European Commission (2013‐0040, Framework Agreement number: 2013-0040)
  • Cerebra
  • Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • Instituto de Salud Carlos III (INT16/00168, PI15/00130, PI14/, PI14/00226, PI15/00130, PI14/00226)
  • European Regional Development Fund
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiovascular Conditions and Treatments
Keywords
fetal growth restriction, cardiovascular disease, low birth weight, metabolic programming, metabolic syndrome, arterial remodeling, subclinical cardiac dysfunction, endothelial dysfunction, cardiovascular mortality, early-onset fetal growth restriction, late-onset fetal growth restriction
MeSH terms
Adaptation, Physiological, Adult, Cardiovascular Diseases, Female, Fetal Growth Retardation, Humans, Male, Pregnancy, Prenatal Exposure Delayed Effects, Ventricular Remodeling, Epigenesis, Genetic, Fetal Development, Atrial Remodeling, Vascular Remodeling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review